Pierre Baumann - ARCHIVE

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


328 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | ...
 
Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie : Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP [Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]
Unterecker S., Hefner G., Baumann P., Gründer G., Bergemann N., Clement H.W., Conca A., Deckert J., Domschke K., Eckermann G. et al., 2019/05. Der Nervenarzt, 90 (5) pp. 463-471. Peer-reviewed.
 
Clinical Psychopharmacology in Switzerland.
Baumann P., 2019. Journal of clinical psychopharmacology, 39 (1) pp. 5-8. Peer-reviewed.
 
Les nouvelles recommandations du groupe AGNP-TDM
Baumann Pierre, Gründer Gerd, Bergemann Niels, Clement Hans Willi, Conca Andreas, Domschke Katharina, Eckermann Gabriel, Egberts Karin, Gerlach Manfred, Silva Gracia Margarete et al., 2019. InFo Neurologie & Psychiatrie, 17 (1) pp. 20-24.
 
Neue Konsensusleitlinien der TDM-Arbeitsgruppe der AGNP
Baumann Pierre, Gründer Gerd, Bergemann Niels, Clement Hans Willi, Conca Andreas, Domschke Katharina, Eckermann Gabriel, Egberts Karin, Gerlach Manfred, Silva Gracia Margarete et al., 2019. InFo Neurologie & Psychiatrie, 17 (1).
 
Konsensus-leitlinien für therapeutisches Drug-Monitoring in der Neuropsychopharmakologie: Update 2017
Hefner Gudrun, Laux Gerd, Baumann Pierre, Bergemann Niels, Clement Hans-Willi, Conca Andreas, Deckert Jürgen, Domschke Katharina, Eckermann Gabriel, Egberts Karin et al., 2018/06/03. Psychopharmakotherapie, 25 pp. 92-140.
 
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians<sup/>.
Schoretsanitis G., Paulzen M., Unterecker S., Schwarz M., Conca A., Zernig G., Gründer G., Haen E., Baumann P., Bergemann N. et al., 2018/04. The world journal of biological psychiatry, 19 (3) pp. 162-174. Peer-reviewed.
Implementation of Therapeutic Drug Monitoring and Pharmacogenetic Tests in Psychiatry: How About ABCB1?
Baumann Pierre, 2018/03/13. Journal of Bioequivalence and Bioavailability, 10 (2) pp. 371-372.
 
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
Hiemke C., Bergemann N., Clement H.W., Conca A., Deckert J., Domschke K., Eckermann G., Egberts K., Gerlach M., Greiner C. et al., 2018/01. Pharmacopsychiatry, 51 (1-02) pp. 9-62. Peer-reviewed.
 
Implémentation de la pharmacogénomique en psychiatrie
Baumann Pierre, 2018. Info Neurologie und Psychiatrie, 16 (2) pp. 37-38.
 
Training in Psychopharmacology- Pharmacopsychiatry for Residents in Psychiatry
Baumann Pierre, 2018. dans Education about Mental Health and Illness, Springer.
 
Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT).
Amstutz U., Mlakar V., Curtis P.H., Samer C., Baumann P., Bühlmann R.P., Meier-Abt P., Meyer U.A., van Schaik RHN, Ansari M. et al., 2017/12/20. Drug metabolism and personalized therapy, 32 (4) pp. 173-174. Peer-reviewed.
 
Pharmacogénomique et thérapie personnalisée
Baumann P., Amstutz U., Bühlmann R.P., Meier-Abt P., Meyer U.A., Samer C., Ansari M., 2017/09/06. Revue medicale suisse, 13 (573) pp. 1544-1545. Peer-reviewed.
A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe.
Baumann P., Spies M., Möller H.J., Kasper S., Bitter I., Laux G., 2017/02. The world journal of biological psychiatry, 18 (1) pp. 29-38. Peer-reviewed.
 
Grundlagen und praktische Hinweise für pharmakogenetische Tests
Baumann Pierre, Amstutz Ursula, Jetter Alexander, Samer Caroline, Ansari Marc, 2017. InFo NEUROLOGIE & PSYCHIATRIE, 15 (6) pp. 21-30.
 
Notions de base et aspects pratiques à propos de tests pharmacogénétiques dans le cadre d'une psychopharmacothérapie
Baumann Pierre, Amstutz Ursula, Jetter Alexander, Samer Caroline, Ansari Marc, 2017. Info Neurologie und Psychiatrie, 15 (6) pp. NA.
 
Psychopharmacology curriculum for psychiatric residents [Konzeptuelle Vorschläge zur Weiterbildung in Psychopharmakologie]
Laux G., Baumann P., Möller H.-J., 2017. Die Psychiatrie - Grundlagen und Perspektiven, 14 (1) pp. 21-27.
 
Psychopharmakologie – Pharmakopsychiatrie
Baumann Pierre, 2017. InFo NEUROLOGIE & PSYCHIATRIE, 15 (6) p. 20.
 
Clinical pharmacological management of polypharmacy in old age depression
Baumann P., Greil W., 2016. pp. S39 dans 24th European Congress of Psychiatry / European Psychiatry.
 
Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004-2011.
Schäfer A., Hiemke C., Baumann P., 2016. Nordic Journal of Psychiatry, 70 (3) pp. 202-207. Peer-reviewed.
Creation of the Swiss group of pharmacogenomics and personalized therapy (SPT)
Mlakar Vid, Huezo Diaz Curtis Patricia, Baumann Pierre, Bühlmann Roland P, Meier-Abt Peter, Meyer Urs A, Ansari Marc, 2016. Schweizer Krebsbulletin 3 p. 264.
 
Création du Groupe Suisse de Pharmacogénomique et de Thérapie Personnalisée (SPT)
Baumann Pierre, Bühlmann Roland P., Jetter Alexander, Kupferschmidt Hugo, Meier-Abt Peter, Meyer Urs A., Ansari Marc, 2016. Pipette - Swiss Laboraty Medicine 3 pp. 17-18.
 
The present situation of psychopharmacology teaching suggests the need for a European curriculum
Baumann P., Laux G., 2016. pp. S62-S63 dans 24th European Congress of Psychiatry / European Psychiatry.
 
Une cardiopathie d'origine inhabituelle
Hungerbühler Philippe, Hedjal Ahmed, Girod Grégoire, Baumann Pierre, Plan Pierre Alain, 2016/01. Revue Médicale Suisse 502 pp. 148-151. Peer-reviewed.
 
Bestrebungen für ein europaweites Curriculum
Spies Marie, Baumann Pierre, Möller Hans-Jürgen, Bitter Istvàn, Laux Gerd, Kasper Siegfried, 2015. CliniCum Neuropsy 6 pp. 8-10.
 
Off Label Use of Other CNS Drugs (e.g.psychostimulants, Anticonvulsants, Lithium): Pro's and Con's
Baumann Pierre, 2015. p. 51 dans 23rd European Congress of Psychiatry, European Psychiatry. Peer-reviewed.
 
A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.
Nelson J.C., Baumann Pierre, Delucchi K., Joffe R., Katona C., 2014. Journal of Affective Disorders, 168 pp. 269-275. Peer-reviewed.
 
CYP2D6 : clinical implications in neuropsychiatry
Baumann Pierre, 2014. pp. 135-151 dans CYP2D6 : genetics, pharmacology and clinical relevance, Future Medicine.
 
CYP2D6 : genetics, pharmacology and clinical relevance
Baumann Pierre (eds.), 2014. 153, Future Medicine.
 
CYP2D6 : genetics, pharmacology and clinical relevance
Baumann Pierre, 2014. pp. 3-6 dans CYP2D6 : genetics, pharmacology and clinical relevance, Future Medicine.
 
EPA-1471 - Polypharmacy in geriatric psychiatry: risks and management of pharmacokinetic interactions
Baumann Pierre, 2014. pp. Suppl. 1 dans 22nd European Congress of Psychiatry, European Psychiatry. Peer-reviewed.
 
Nachruf auf Christian Müller (1921-2013)
Ciompi L., Baumann Pierre, 2014. Der Nervenarzt, 85 (9) pp. 1182-1183. Peer-reviewed.
 
Pharmacovigilance en psychiatrie : données récentes
Baumann Pierre, 2014. pp. 661-662 dans 6ème Congrès Français de Psychiatrie, European Psychiatry. Peer-reviewed.
 
The AMSP-project: Pharmacovigilance in psychiatry - Presentation, challenges and results
Baumann Pierre, 2014. p. 663 dans 6ème Congrès Français de Psychiatrie, European Psychiatry. Peer-reviewed.
 
Therapeutic Drug Monitoring
Baumann Pierre, 2014. pp. 1-9 dans Stolerman Ian P., Price Lawrence H. (eds.) Encyclopedia of Psychopharmacology, Springer.
 
Therapeutisches Drug-Monitoring in der Psychiatrie : Kurze Zusammenfassung des neuen Konsensuspapiers der Arbeitsgruppe TDM der AGNP [Therapeutic drug monitoring in psychiatry : A brief summary of the new consensus paper by the task force on TDM of the AGNP].
Gründer G., Baumann P., Conca A., Zernig G., Hiemke C., für die TDM-Gruppe der AGNP, 2014. Der Nervenarzt, 85 (7) pp. 847-855. Peer-reviewed.
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Greil W., Häberle A., Schuhmann T., Grohmann R., Baumann Pierre, 2013. Swiss Medical Weekly, 143 pp. w13772. Peer-reviewed.
 
Biologische Psychiatrie der Gegenwart : 3. Drei-Länder-Symposium für Biologische Psychiatrie Lausanne, September 1992
Baumann P., Fleischhacker W.W., Gaebel W., Laux G., Möller H.-J., Saletu B., Woggon B. (eds.), 2013. 804, Springer.
 
Dosage plasmatique des medicaments antidépresseurs [Recommendations for therapeutic monitoring of antidepressants].
Baumann P., Rougemont M., Corruble E., Hiemke C., Groupe AGNP-DPM, 2013. Revue Médicale Suisse, 9 (377) pp. 577-586. Peer-reviewed.
 
Psychopharmakotherapie nach restricktiven gastrointestinalen Eingriffen: Fallbericht und Literaturübersicht
Baumann Pierre, Trégouët Olivier, 2013. Psychopharmakotherapie, 20 (1) pp. 31-37. Peer-reviewed.
 
Transport Mechanisms of Tryptophan in Blood Cells, Nerve Cells, and at the Blood-Brain Barrier : Proceedings of the International Symposium, Prilly/Lausanne, Switzerland, July 6-7, 1978
Baumann P. (eds.), 2013. Journal of Neural Transmission 237, Springer.
 
Neue Empfehlungen für das Therapeutische Drug Monitoring in der Psychiatrie
Baumann Pierre, Hiemke Christoph, 2012/08. Pipette : Swiss Laboratory Medicine 4 pp. 15-16.
 
AGNP-Konsensus-Leitlinien für therapeutisches Drug-Monitoring in der Psychiatrie: Update 2011
Hiemke Christoph, Baumann Pierre, Bergemann Niels, Conca Andreas, Dietmaier Otto, Egberts Karin, Fric Mirijam, Gerlach Manfred, Greiner Christine, Gründer Gerhard et al., 2012. Psychopharmakotherapie, 19 (3) pp. 91 - 122.
 
Az AGNP konszenzuson alapulo iranyelvi a terapias gyogyszerzint monitorozasahaoz a pszichiatriaban
Hiemke C., Baumann P., Bergemann N., Conca A., Dietmaier O., Egberts K., Fric M., Gerlach M., Greiner C., Gründer G. et al., 2012. Psychiatria Hungarica, 27 (Suppl. 1) pp. 7-64.
 
Citation of the AGNP consensus guidelines for therapeutic drug monitoring in psychiatry 2004 in the scientific literature 2004 to 2011
Schäfer A., Hiemke C., Baumann P., 2012. pp. 45 - A20 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
 
Clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression
Jaquenoud Sirot E., Harenberg S., Vandel P., Mendonça Lima C.A., Perrenoud P., Kemmerling K., Zullino D.F., Hilleret H., Crettol S., Jonzier-Perey M. et al., 2012. pp. 45 - A10 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
 
Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.
Urben S., Baumann P., Barcellona S., Hafil M., Preuss U., Peter-Favre C., Clarke S., Halfon O., Holzer L., 2012. Psychiatric Quarterly, 83 (3) pp. 311-324. Peer-reviewed.
 
Drug Interaction Probability Scale: Ein nützliches Instrument zur Abklärung von unerwünschten Arzneimittelwirkungen
Schuhmann T., Baumann P., 2012. InFo Neurologie und Psychiatrie, 10 (3) pp. 30-33.
 
Flupentixol: relevance of stereoselective therapeutic drug monitoring.
Baumann P., Kirchherr H., Berney P., Hiemke C., 2012. Psychopharmacology, 221 (4) pp. 719-720. Peer-reviewed.
 
Matched case-control study: therapeutic drug monitoring in pharmacovigilance
Jaquenoud Sirot E., Stephan P.L., Eap C.B., van der Velden J.W., Baumann P., 2012. pp. 45 - A11 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
 
Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression.
Jaquenoud Sirot E., Harenberg S., Vandel P., Lima C.A., Perrenoud P., Kemmerling K., Zullino D.F., Hilleret H., Crettol S., Jonzier-Perey M. et al., 2012. Journal of Clinical Psychopharmacology, 32 (5) pp. 622-629. Peer-reviewed.
 
Neue Empfehlungen für das Therapeutische Drug Monitoring: Bedeutung für die Arzneimittelsicherheit in der Psychiatrie
Baumann Pierre, Jaquenoud Sirot Eveline, Schwarz Markus, Hiemke Christoph, 2012. Info Neurologie & Psychiatrie : interdisziplinäre Fortbildung in der Neurologie, Psychiatrie und Psychotherapie, 10 (4) pp. 38-40.
 
Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring
Hiemke C., Baumann P., Stingl J., 2012. pp. 441 - 464 dans Gründer G., Benkert O. (eds.) Handbuch der psychiatrischen Pharmakotherapie, Springer.
 
Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response.
Nikisch G., Baumann P., Liu T., Mathé A.A., 2012. International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (cinp), 15 (8) pp. 1051-1061. Peer-reviewed.
 
TDM in patients with substance related disorders
Havemann-Reinecke U., Bruenen S., Vincent P., Baumann P., Hiemke C., 2012. p. 1 dans 20th European Congress of Psychiatry, European Psychiatry. Peer-reviewed.
 
The AGNP-TDM expert group consensus guidelines 2004 -therapeutic drug monitoring in psychiatry: Analysis of 199 citations (2004 - 2011)
Baumann P., Hiemke C., 2012. p. 1 dans 20th European Congress of Psychiatry, European Psychiatry. Peer-reviewed.
 
Viktor von Weizsäcker et le national-socialisme [Viktor von Weizsäcker and national socialism].
Baumann P., 2012. Revue Médicale Suisse, 8 (333) pp. 655; discussion 656.
 
A new rating scale to evaluate the potential benefit of therapeutic drug monitoring
Bruenen S., Vincent P.D., Baumann P., Hiemke C., Havemann-Reinecke U., 2011. pp. 499-500 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Therapeutic Drug Monitoring. Peer-reviewed.
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.
Hiemke C., Baumann P., Bergemann N., Conca A., Dietmaier O., Egberts K., Fric M., Gerlach M., Greiner C., Gründer G. et al., 2011. Pharmacopsychiatry, 44 (6) pp. 195-235. Peer-reviewed.
 
Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.
Nikisch G., Baumann P., Oneda B., Kiessling B., Weisser H., Mathé A.A., Yoshitake T., Kehr J., Wiedemann G., Eap C.B., 2011. Journal of Psychopharmacology, 25 (7) pp. 896-907. Peer-reviewed.
 
Die schweizerische Gesellschaft für Arzneimittelsicherheit in der Psychiatrie
Baumann Pierre, Angst Katrin, Brunner Sandra, Eich Philipp, Giachino Philipp, Hasler Gregor, Jaquenoud Sirot Eveline, Horvath Andreas, Keck Marin, Schuhmann Thomas et al., 2011. InFo Neurologie und Psychiatrie, 9 (1) p. 43.
 
Drug interactions in the treatment of Bipolar disorder
Baumann Pierre, 2011. p. 2028 dans 19th European Congress of Psychiatry, European Psychiatry. Peer-reviewed.
 
Escitalopram in der klinischen Praxis: eine Erhebung von Praxiserfahrungen bei Patienten mit Depressionen und Angstörungen
Holsboer-Trachsler Edith, Baumann Pierre, Höck Paul, Hättenschwiler Josef, Jost Martin, Ramseier Fritz, Seifritz Erich, Nil Rico, 2011. Psychopharmakotherapie: Arzneimitteltherapie psychischer und neurologischer Erkrankungen, 18 (2) pp. 59-65.
 
Multimorbidität und Polypharmazie in der Psychiatrie
Baumann Pierre, Greil Waldemar, 2011. pp. 58-59 dans 9. SGAMSP-Jahrestagung, InFo Neurologie und Psychiatrie.
 
Pharmacokinetics of psychotropic drugs - keys for treatments' improvements
Baumann Pierre, 2011. p. 1995 dans 19th European Congress of Psychiatry, European Psychiatry. Peer-reviewed.
 
Quetiapine in adolescents with non-affective psychotic disorders: an open-label trial.
Holzer L., Preuss U., Baumgartner L., Jaugey L., Urben S., Halfon O., Baumann P., 2011. Pharmacopsychiatry, 44 (3) pp. 87-95. Peer-reviewed.
 
Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale.
Brünen S., Vincent P.D., Baumann P., Hiemke C., Havemann-Reinecke U., 2011. Therapeutic Drug Monitoring, 33 (5) pp. 561-572. Peer-reviewed.
 
Therapeutic drug monitoring in psychiatry.
Conca A., Baumann P., Hiemke C., 2011. Pharmacopsychiatry, 44 (6) pp. 193-194. Peer-reviewed.
 
Therapeutic drug monitoring of drugs for treatment of substance-related disorders
Brünen S., Vincent P.D., Baumann P., Hiemke C., Havemann-Reinecke U., 2011. p. 13 dans 19th European Congress of Psychiatry, European Psychiatry. Peer-reviewed.
 
Vade-mecum de thérapeutique psychiatrique
Calanca Aldo (eds.), 2011., 10e éd. entièrement rév. et augm. 220, Médecine et hygiène.
 
Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza
Goodwin Guy, Fleischhacker Wolfgang, Arango Celso, Baumann Pierre, Davidson Michael, de Hert Marc, Falkai Peter, Kapur Shitij, Leucht Stefan, Licht Rasmus et al., 2011. Psiquiatría Biológica, 18 (2) pp. 55-67. Peer-reviewed.
 
Viktor von Weizsäcker et le national-socialisme : à propos de la Carte blanche du Pr Marco Vannotti : pathosophie ou l'objet de la médecine
Baumann Pierre, 2011. Revue médicale suisse 333 p. 655.
 
French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs.
Rougemont M., Ulrich S., Hiemke C., Corruble E., Baumann P., 2010/06. Fundamental & clinical pharmacology, 24 (3) pp. 377-384. Peer-reviewed.
 
Burnout: eine Standortbestimmung
Nil Rico, Jacobshagen Nicola, Schächinger Hartmut, Baumann Pierre, Höck Paul, Hättenschwiler Josef, Ramseier Fritz, Seifritz Erich, Holsboer-Trachsler Edith, 2010. Schweizer Archiv für Neurologie und Psychiatrie = Archives Suisses de Neurologie et de Psychiatrie = Archivio Svizzero Di Neurologia E Psichiatria, 161 (2) pp. 72-77. Peer-reviewed.
 
Pharmakogenetik
Baumann Pierre, 2010. pp. 337-351 dans Riederer Peter F., Laux Gerd (eds.) Grundlagen der Neuro-Psychopharmakologie : ein Therapiehandbuch, Springer.
 
Pharmakokinetik. Allgemeine Grundlagen
Müller Walter E., Hiemke Christoph, Baumann Pierre, 2010. pp. 289-303 dans Riederer Peter F., Laux Gerd (eds.) Grundlagen der Neuro-Psychopharmakologie : ein Therapiehandbuch, Springer.
 
Professeur Alfred Bader: une nécrologie
Baumann Pierre, 2010. Schweizer Archiv für Neurologie und Psychiatrie = Archives Suisses de Neurologie et de Psychiatrie = Archivio Svizzero Di Neurologia E Psichiatria, 161 (1) pp. 46-47. Peer-reviewed.
 
Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with l- and d,l-methadone.
Wedekind D., Jacobs S., Karg I., Luedecke C., Schneider U., Cimander K., Baumann P., Ruether E., Poser W., Havemann-Reinecke U., 2010. World Journal of Biological Psychiatry, 11 (2 Pt 2) pp. 390-399. Peer-reviewed.
 
Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF.
Nikisch G., Baumann P., Wiedemann G., Kiessling B., Weisser H., Hertel A., Yoshitake T., Kehr J., Mathé A.A., 2010. Journal of Clinical Psychopharmacology, 30 (5) pp. 496-503. Peer-reviewed.
 
Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
Nikisch G., Baumann P., Kiessling B., Reinert M., Wiedemann G., Kehr J., Mathé A.A., Piel M., Roesch F., Weisser H. et al., 2010. Journal of Psychiatric Research, 44 (12) pp. 754-759. Peer-reviewed.
 
SPCCtdm, a Catalogue for analysis of Therapeutic drug Monitoring related Contents in the drug Prescription Information
Ulrich Sven, Baumann Pierre, Conca Andreas, Kuss Hans-Joachim, Stieffenhofer Viktoria, Hiemke Christoph, 2010. International Journal of Knowledge Discovery in Bioinformatics, 1 (2) pp. 1-11. Peer-reviewed.
 
Spezielle Pharmakokinetik
Müller Walter E., Hiemke Christoph, Baumann Pierre, 2010. pp. 305-312 dans Riederer Peter F., Laux Gerd (eds.) Grundlagen der Neuro-Psychopharmakologie : ein Therapiehandbuch, Springer.
 
Therapeutic Drug Monitoring
Baumann Pierre, 2010. pp. 1307-1313 dans Stolerman Ian P. (eds.) Encyclopedia of Psychopharmacology, Springer.
 
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E., Knezevic B., Morena G.P., Harenberg S., Oneda B., Crettol S., Ansermot N., Baumann P., Eap C.B., 2009. Journal of clinical psychopharmacology, 29 (4) pp. 319-26. Peer-reviewed.
 
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G., Fleischhacker W., Arango C., Baumann P., Davidson M., de Hert M., Falkai P., Kapur S., Leucht S., Licht R. et al., 2009. European Neuropsychopharmacology, 19 (7) pp. 520-532. Peer-reviewed.
 
Cardiac left bundle branch block and pancytopenia in anorexia nervosa: higher risk with mirtazapine and pantoprazole? Case report.
Walder A., Baumann P., 2009. Pharmacopsychiatry, 42 (2) pp. 79-81. Peer-reviewed.
 
Drug-induced Pisa syndrome under quetiapine.
Walder A., Greil W., Baumann P., 2009. Progress in neuro-psychopharmacology & biological psychiatry, 33 (7) pp. 1286-7. Peer-reviewed.
 
Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions ?
Walder alice, Baumann Pierre, 2009. Acta Medica (Hradec Kralove), 52 (1) pp. 15-18. Peer-reviewed.
 
Nachruf : Prof. Alfred Bader = Nécrologie : Professeur Alfred Bader
Baumann Pierre, 2009. Psy and Psy 2 p. 22.
 
Polymedication in elderly psychiatric patients suffering from comorbidities: risks for pharmacokinetic interactions with clinical consequences
Baumann Pierre, 2009/01., 17th European congress of psychiatry, January 24-28, 2009, Lisbon, Portugal pp. S48-03 dans , European psychiatry. Peer-reviewed.
 
Prescription off-label et troubles bipolaires: questions en pratique clinique
Baumann Pierre, 2009. Psy & Psy 2 pp. 10-11.
 
Psychopharmaka - Off-Label-Use (1/2)
Baumann Pierre, Voirol Pierre, 2009. PharmaJournal, 22 pp. 4-7.
 
Psychopharmaka - Off-Label-Use (2/2)
Baumann Pierre, Voirol Pierre, 2009. PharmaJournal, 23 pp. 4-6.
 
Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour
Lind Anna-Britta, Reis Margareta, Bengtsson Finn, Jonzier Perey Michèle, Powell Golay Kerry, Ahlner Johan, Baumann Pierre, Dahl Marja-Liisa, 2009. Clinical Pharmacokinetics, 48 (1) pp. 63-70. Peer-reviewed.
 
Therapeutic drug monitoring and pharmacogenetic tests in pharmacovigilance - when and what ?
Jaquenoud Sirot E., Baumann P., 2009/01., 17th European congress of psychiatry, January 24-28, 2009, Lisbon, Portugal pp. S20-02 dans , European Psychiatry. Peer-reviewed.
 
Utilisation «off label» des médicaments psychotropes (1/2)
Baumann Pierre, Voirol Pierre, 2009. PharmaJournal, 22 pp. 7-10.
 
Utilisation «off label» des médicaments psychotropes (2/2)
Baumann Pierre, Voirol Pierre, 2009. PharmaJournal, 23 pp. 8-10.
 
"Therapeutic drug monitoring" in Epileptologie und Psychiatrie [Therapeutic drug monitoring in epileptology and psychiatry]
Brandt Christian, Baumann Pierre, Hiemke Christoph, May T.W., Rambeck B., Pohlmann-Eden B., 2008. Der Nervenarzt, 79 (2) pp. 167-174. Peer-reviewed.
 
ABCB1 and cytochromes P450 genotypes and phenotypes: influence on clozapine plasma concentrations
Jaquenoud Sirot Eveline, Knezevic B., Perla Morena Gina, Baumann Pierre, Eap Chin Bin, 2008. pp. e465 dans , Canadian Journal of Clinical Pharmacology = Journal canadien de pharmacologie clinique. Peer-reviewed.
 
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.
Nikisch G., Eap C.B., Baumann P., 2008. Pharmacological research, 58 (5-6) pp. 344-347. Peer-reviewed.
 
Dysfonctions sexuelles induites par les antidépresseurs et les antipsychotiques et leurs traitements
Martin-Du Pan Rémy, Baumann Pierre, 2008. Revue médicale suisse, 4 (150) pp. 758-762. Peer-reviewed.
 
Effect of the NMDA-receptor antagonist dextromethorphan in infant rat pneumococcal meningitis.
Sellner J., Ringer R., Baumann P., Perey M.J., Schmitt B., Leib S.L., 2008. Current Drug metabolism, 9 (1) pp. 83-88. Peer-reviewed.
 
Gestörte Chronobiologie begüngstigt Depressionen: Resynchronisierung als Wirkprinzip
Baumann Pierre, 2008. Leading Opinions. Neurologie und Psychiatrie, 8 (4) pp. 8-10.
 
Increased creatinine kinase and rhabdomyolysis in anorexia nervosa.
Walder A., Baumann P., 2008. International Journal of Eating Disorders, 41 (8) pp. 766-767. Peer-reviewed.
 
Metabolism of psychotropic drugs in the human brain: significance for therapeutic drug monitoring ?
Baumann Pierre, 2008. dans Pharmacopsychiatrie, Pharmacopsychiatry. Peer-reviewed.
 
Nutzen und Aktualität der Fachinformationen für das therapeutische Drug-Monitoring von Psychopharmaka: ein Vergleich mit der Evidenz aus der Literatur
Ulrich Sven, Laux Gerd, Müller-Oerlinghausen Bruno, Havemann-Reinecke Ursula, Riederer Peter, Zernig Gerald, Baumann Pierre, Hiemke Christoph, 2008. Psychopharmakotherapie, 15 (2) pp. 67-74. Peer-reviewed.
 
Off-label utilization of antidepressants.
Zullino D.F., Schwartz B., Bilancioni R., Baumann P., 2008. Acta Medica (hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové, 51 (1) pp. 19-24. Peer-reviewed.
 
Pharmacogenetics of clozapine: in vivo role of cytochrome P450 isoforms and P-Glycoprotein
Jaquenoud Sirot Eveline, Knezevic B., Perla Morena Gina, Baumann Pierre, Eap Chin Bin, 2008. dans Pharmacopsychiatry, Pharmacopsychiatry. Peer-reviewed.
 
Pharmacovigilance in psychiatry: pharmacogenetic tests and therapeutic drug monitoring are promising tools
Baumann P., 2008. Expert Review of Clinical Pharmacology, 1 (2) pp. 183-185. Peer-reviewed.
 
Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring
Hiemke C., Baumann P., 2008. pp. 375-397 dans Holsboer Florian, Gründer Gerhard, Benkert Otto (eds.) Handbuch der Psychopharmakotherapie, Springer.
 
Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with l- and d,l-methadone.
Wedekind D., Jacobs S., Karg I., Luedecke C., Schneider U., Cimander K., Baumann P., Ruether E., Poser W., Havemann-Reinecke U., 2008. World Journal of Biological Psychiatry, 9 pp. 1-10. Peer-reviewed.
 
Purpura and ecchymosis under carbamazepine, chloral hydrate and melitracen-flupentixol.
Walder A., Greil W., Baumann P., 2008. European Journal of Dermatology, 18 (1) pp. 103-104. Peer-reviewed.
 
Quetiapine in adolescents with psychosis: a 12 weeks open label trial
Holzer Laurent, Preuss Ulrich, Clarke Stephanie, Halfon Olivier, Baumann Pierre, 2008. p. 162 dans Schizophrenia Research, Schizophrenia Research. Peer-reviewed.
 
Spezielle Arzneimittelinteraktionen
Hiemke C., Baumann P., 2008. pp. 1127-1144 dans Holsboer Florian, Gründer Gerhard, Benkert Otto (eds.) Handbuch der Psychopharmakotherapie, Springer.
 
TDMplus: the combination of TDM, check for drug interactions and genotyping
Jaquenoud Sirot Eveline, Baumann Pierre, 2008. pp. A19 dans 5th Regensburg Symposium on Clinical Pharmacology - of Therapeutical Drug Monitoring - 8th Workshop of the TDM Workgroup of AGNP, Pharmacopsychiatry. Peer-reviewed.
 
Terapia antidepressantami i dugie metodi letchenja depressivnich rasstoist
Sartorius Norman, Baghai Thomas C., Baldwin David S., Barrett Barbara, Brand Ursula, Fleischhacker Wolfgang, Goodwin Guy, Grunze Heinz, Knapp Martin, Leonard Brian E. et al., 2008. 215, Rossiiskoje obchestvo pcichjatrov.
 
Text analysis and drug analysis: therapeutic drug monitoring in the prescription information
Ulrich Sven, Hiemke Christoph, Conca Antoinette, Kuss Hans-Joachim, Tatusch V., Baumann Pierre, 2008. p. 216 dans , Pharmacopsychiatry. Peer-reviewed.
 
The AGNP-TDM expert consensus guidelines 2004: a promising start !
Baumann Pierre, 2008. dans Pharmacopsychiatrie, Pharmacopsychiatry. Peer-reviewed.
 
Therapeutic monitoring of psychotropic drugs to improve compliance
Baumann Pierre, 2008. p. 86 dans International Journal of Neuropsychopharmacology, International Journal of Neuropsychopharmacology. Peer-reviewed.
 
Traitement pharmacologique de la schizophrénie: évaluation comparative de la qualité des recommandations de pratique clinique [Comparative evaluation of clinical practice guidelines for the treatment of schizophrenia]
Delessert D., Pomini V., Grasset F., Baumann P., 2008. L'Encéphale, 34 (1) pp. 93-100. Peer-reviewed.
 
Wie wirksam sind Antidepressiva ?: zur Bedeutung von Plasmakonzentrations-Wirksamkeits-Studien
Hiemke Christoph, Ulrich Sven, Baumann Pierre, Broich Karl, Conca Andreas, Havemann-Reinecke Ursula, Gerlach Manfred, Haen Ekkehard, Laux Gerd, Müller-Oerlinghausen Bruno et al., 2008. Psychopharmakotherapie, 15 (4) pp. 162-163. Peer-reviewed.
 
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.
Sartorius N., Baghai T.C., Baldwin D.S., Barrett B., Brand U., Fleischhacker W., Goodwin G., Grunze H., Knapp M., Leonard B.E. et al., 2007. International Journal of Neuropsychopharmacology, 10 (Suppl. 1) pp. S1-S207. Peer-reviewed.
 
Dépression: le point sur les traitements psychopharmacologiques
Baumann Pierre, 2007. Revue médicale suisse, 3 (125) pp. 2079-2084.
 
Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study
Le Bloc'h Yves, Baumann Pierre, Stigler Michael, Eap Chin-Bin, Zullino Daniele Fabio, 2007. International Journal of Psychiatry in Clinical Practice, 11 (2) pp. 123-128. Peer-reviewed.
 
Les antidépresseurs favorisent-ils la suicidalité et le suicide chez les individus dépressifs?
Hättenschwiller Joseph, Baumann Pierre, Hatzinger Martin, Höck Paul, Holsboer-Trachsler Edith, Jost Martin, Nil Rico, Ramseier Fritz, Seifritz Erich, Zullino Daniele et al., 2007. Swiss Medical Forum = Forum Médical Suisse, 7 (37) pp. 757-764. Peer-reviewed.
 
Pharmacokinetic influences on treatment of the elderly
Baumann Pierre, 2007. pp. 296-340 dans , International Journal of Psychiatry in Clinical Practice. Peer-reviewed.
 
Problem solving in psychopharmacotherapy using pharmacokinetic and pharmacogenetic tests
Baumann Pierre, Jaquenoud Sirot Eveline, Hiemke Christoph, Bengtsson Finn, 2007. p. 96 dans , European Psychiatry. Peer-reviewed.
 
Recommandations de pratique clinique dans la schizophrénie: de la théorie à la mise en application = Clinical practice guidelines for the treatment of schizophrenia: from theory to practice
Delessert D., Pomini V., Grasset F., Baumann P., 2007. Encéphale, 33 (6) pp. 902-910. Peer-reviewed.
 
Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?
Mathé A.A., Husum H., El Khoury A., Jiménez-Vasquez P., Gruber S.H., Wörtwein G., Nikisch G., Baumann P., Agren H., Andersson W. et al., 2007. Physiology and Behavior, 92 (1-2) pp. 226-231. Peer-reviewed.
 
Selective serotonin reuptake inhibitors in adolescent depression still controversial
Holzer L., Baumann P., 2007. Journal of clinical psychopharmacology, 27 (3) pp. 325-6; author reply 326. Peer-reviewed.
 
Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence
Ulrich Sven, Hiemke Christoph, Laux Gerd, Müller-Oerlinghausen Bruno, Havemann-Reinecke U., Riederer Peter, Zernig Gerald, Baumann Pierre, 2007. Pharmacopsychiatry, 40 (3) pp. 121-127. Peer-reviewed.
 
Psychotropic drug prescriptions in hospitalized elderly psychiatric patients: comparison with adult psychiatric patients
ZULLINO Daniele F., REYNAUD Gilbert, DE MENDONCA LIMA Carlos Augusto, BAUMANN Pierre, 2006/06. Psychogeriatrics, 6 (2) pp. 68-73. Peer-reviewed.
 
Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity
Stephan P.L., Jaquenoud Sirot E., Mueller B., Eap C.B., Baumann P., 2006. Pharmacopsychiatry, 39 (4) pp. 150-2. Peer-reviewed.
Apport de la pharmacogénétique dans le traitement médicamenteux des addictions : l'exemple de la méthadone
Eap C.B., Baumann P., 2006. pp. 65-70 dans Suchtforschung des BAG. Recherches de l'OFSP en matière de dépendances 2002-03, Bundesamt für Gesundheit.
 
Clinical relevance of TDM of SSRIs
Schwarz Markus J., Hiemke Christoph, Baumann Pierre, 2006. Therapeutic Drug Monitoring, 28 (5) pp. 716-717. Peer-reviewed.
 
Dose-dependent venlafaxine-induced hair loss
Jaquenoud Sirot Eveline, Etzensberger M., Eap Chin-Bin, Baumann Pierre, 2006. p. 939 dans , Drug Safety. Peer-reviewed.
Drug monographs on drugs which are frequently analysed in the context of Therapeutic Drug Monitoring = Arzneimittel-Monographien für Medikamente, die regelmässig im Rahmen des Therapeutic Drug Monitorings analysiert werden
Rentsch Katharina, Baumann Pierre, Fathi Marc, Grignaschi Nathalie, Magnin Jean-Luc, Thormann Wolfgang, Todesco Liliane, Wenk Markus, Werner Dominique, 2006. LaboratoriumsMedizin = Journal of Laboratory Medicine, 30 (6) pp. 443-452. Peer-reviewed.
 
Epidemiology of major depression: how is the view changing ?
Schlaepfer T.E., Baumann Pierre, 2006. pp. 13-14 dans , Parkinsonism and Related Disorders. Peer-reviewed.
 
Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status.
Baumann P., Barbe R., Vabre-Bogdalova A., Garran E., Crettol S., Eap C.B., 2006. Journal of clinical psychopharmacology, 26 (6) pp. 679-81. Peer-reviewed.
 
Le dosage plasmatique des médicaments psychotropes à des fins thérapeutiques: recommandations du groupe d'experts AGNP-TDM
Baumann Pierre, Hiemke Christoph, Ulrich Sven, Eckermann Gabriel, Kuss H.L., Laux Gerd, Muller-Oerlingenhausen B., Rao Marie Luise, Riederer Peter, Zernig Gerald, 2006. Revue médicale suisse, 2 (67) pp. 1413-1418. Peer-reviewed.
 
Mirtazapine enantiomers in blood and cerebrospinal fluid
Baumann Pierre, Jonzier Perey Michèle, Paus Erik, Nikisch Georg, 2006. Neuropsychobiology, 54 (3) pp. 179-181. Peer-reviewed.
 
Neuropeptide Y (NPY) and corticotropinreleasing hormone (CRH) in human CSF and in brain of animal models of depression
Mathé Aleksander A., Agren Hans, Andersson Weronica, Baumann Pierre, El Khoury Aram, Gruber Susanne H.M., Jiménez-Vasquez Patricia, Nikisch Georg, Wörtwein Gitta, 2006. p. 74 dans , International Journal of Neuropsychopharmacology. Peer-reviewed.
 
Neuropeptides in human cerebrospinal fluid and in brains of animal models of depression - effects of treatment
Mathé Aleksander A., Nikisch Georg, Agren Hans, Baumann Pierre, El Khoury Aram, Gruber Susanne H.M., Husum Henriette, Jiménez-Vasquez Patricia, Wörtwein Gitta, Andersson Weronica et al., 2006. pp. 308-309 dans , European Neuropsychopharmacology. Peer-reviewed.
 
Off-label utilization of antipsychotics
Zullino Daniele Fabio, Bilancioni Romain, Conus Philippe, Schwartz B., Khazaal Yasser, Baumann Pierre, 2006. South African Psychiatry Review, 9 (1) pp. 38-43. Peer-reviewed.
 
Pharmacokinetics and interaction in old age
Baumann Pierre, 2006. p. 319 dans , International Journal of Psychiatry in Clinical Practice. Peer-reviewed.
 
Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening.
Bonsack C., Camus D., Kaufmann N., Aubert A.C., Besson J., Baumann P., Borgeat F., Gillet M., Eap C.B., 2006. Addictive behaviors, 31 (7) pp. 1252-8. Peer-reviewed.
 
Problem solving in psychopharmacotherapy using pharmacokinetic and pharmacogenetic tests
Baumann Pierre, 2006. p. 64 dans , European Psychiatry. Peer-reviewed.
 
Recommandations du groupe d'experts AGNP-TDM: le monitoring à but thérapeutique des médicaments psychotropes
Baumann Pierre, 2006. pp. 26-27 dans , European Psychiatry. Peer-reviewed.
 
Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.
Jaquenoud Sirot E., van der Velden J.W., Rentsch K., Eap C.B., Baumann P., 2006. Drug safety, 29 (9) pp. 735-768. Peer-reviewed.
 
Antidepressiva : Pharmakologie, therapeutischer Einsatz und Klinik der Depressionen
Breyer-Pfaff Ursula, Gaertner Hans Jörg, Baumann Pierre, 2005., 2., völlig neu bearb. Aufl. 159, WVG.
 
Association between plasma and cerebrospinal fluid (CSF) concentrations of SSRI's and newer antidepressants and their metabolites with 5-hydroxyindoleacetic (5-HIAA) and clinical outcom in depressed patients
Nikisch Georg, Mathé Aleksander A., Baumann Pierre, 2005. p. 95 dans , World Journal of Biological Psychiatry. Peer-reviewed.
 
Citalopram - Plasma- und Liquor- konzentrationen: Zusammenhand mit neurobiologischen und klinischen Verlaufsparametern
Nikisch Georg, Mathé Aleksander A., Baumann Pierre, 2005. Psychopharmakotherapie, 12 (4) pp. 130-134. Peer-reviewed.
 
Clinical relevance of citalopram (CIT) plasma and cerebrospinal fluid (CSF) concentrations: impact with CSF monoamine metabolites
Nikisch C., Mathé Aleksander A., Baumann Pierre, 2005. p. 59 dans , Pharmacopsychiatry. Peer-reviewed.
 
CYP2D6 genotype in relation to steady state concentrations of mirtazapine, N-desmethylmirtazapine and their enantiomers
Lind A.B., Reis M., Bengtsson Finn, Ahlner Johan, Eap Chin-Bin, Baumann Pierre, Dahl M.L., 2005. p. 124 dans , Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients.
de Mendonça Lima C.A., Baumann P., Brawand-Amey M., Brogli C., Jacquet S., Cochard N., Powell-Golay K., Eap C.B., 2005. Progress in neuro-psychopharmacology & biological psychiatry, 29 (6) pp. 952-6. Peer-reviewed.
 
Fate of psychotropic drugs at the blood-brain-barrier and in the brain: pharmacokinetic, pharmacodynamic and clinical consequences
Baumann Pierre, Nikisch Georg, Tauscher J., 2005. p. 120 dans , European Psychiatry. Peer-reviewed.
 
Follow-up of a pharmacovigilance study in psychiatry involving TDM and pharmacogenetic testing
Jaquenoud Sirot Eveline, Eap Chin-Bin, Baumann Pierre, 2005. pp. 54-55 dans , Pharmacopsychiatry. Peer-reviewed.
 
Genetic polymorphisms of psychotropic drug metabolizing enzymes: clinical relevance
Baumann Pierre, Jaquenoud Eveline, Eap Chin-Bin, 2005. p. 103 dans , European Psychiatry. Peer-reviewed.
 
High sedation with low doses of atypical antipsychotics in 3 young patients (13 to 14 years old)
Holzer Laurent, Eap Chin-Bin, Halfon Olivier, Baumann Pierre, 2005. p. 53 dans , Pharmacopsychiatry. Peer-reviewed.
 
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients.
Bondolfi G., Morel F., Crettol S., Rachid F., Baumann P., Eap C.B., 2005. Therapeutic drug monitoring, 27 (4) pp. 539-43. Peer-reviewed.
 
Influence of CYP2B6 polymorphism on the steady-state plasma levels of the enantiomers of methadone
Crettol Séverine, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Gottuey I., Haemming R., Monnat Martine, Haottemann H., Baumann Pierre, Eap Chin-Bin, 2005. p. 121 dans NA, Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
International meeting on pharmacovigilance in psychiatry, therapeutic drug monitoring and pharmacogenetics of psychotropic drugs
Baumann Pierre, Aldenhoff Joseph, 2005. Pharmacopsychiatry, 38 (1) p. 41. Peer-reviewed.
 
Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
Nikisch G., Mathé A.A., Czernik A., Thiele J., Bohner J., Eap C.B., Agren H., Baumann P., 2005. Psychopharmacology, 181 (4) pp. 751-60. Peer-reviewed.
 
Metabolism of citalopram by MAO: pharmacogenetic and kinetic animal studies
Paus Erik, Lepore M., Jonzier Perey Michèle, Rochat B., Hornung J.P., Baumann Pierre, 2005. p. 59 dans , Pharmacopsychiatry. Peer-reviewed.
 
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S., Déglon J.J., Besson J., Croquette-Krokkar M., Gothuey I., Hämmig R., Monnat M., Hüttemann H., Baumann P., Eap C.B., 2005. Clinical pharmacology and therapeutics, 78 (6) pp. 593-604. Peer-reviewed.
 
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram.
Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., Mathé A.A., 2005. International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (cinp), 8 (3) pp. 403-410. Peer-reviewed.
 
Neuropeptides in CNS of depressed patients and "depressed" animals: effect fo antidepressant treatments
Mathé Aleksander A., Baumann Pierre, Husum Henriette, Jiménez Patricia, Nikisch Georg, Agren Hans, 2005. p. 96 dans , World Journal of Biological Psychiatry. Peer-reviewed.
 
Optimisation of psychopharmacotherapy: clinical relevance of pharmacogenetic tests and therapeutic drug monitoring
Baumann Pierre, Jaquenoud Sirot Eveline, Eap Chin-Bin, 2005. p. 229 dans , Pharmacopsychiatry. Peer-reviewed.
 
Pharmacokinetics and pharmacogenetics of methadone : clinical relevance
Eap Chin-Bin, Déglon Jean-Jacques, Baumann Pierre, 2005. dans Heroin-assisted treatment : work in progress / ed. by Margret Rihs-Middel...[et al.]. - Bern : H. Huber, 2005. - P. 251-265. - ISBN 3-456-83899-9.
 
Plasma-CSF concentrations relationship of psychotropic drugs
Baumann Pierre, Nikisch Georg, Eap Chin-Bin, 2005. p. 43 dans , Pharmacopsychiatry. Peer-reviewed.
 
Prescribing practices in German and Swiss psychiatric university and in non-university hospitals : national differences
Zullino Daniele Fabio, Mayland G., Schmidt L.G., Fähndrich E., Greil Waldemar, Horvath Andreas, Rüther Eckhardt, Engel R., Hippius H., Baumann Pierre, 2005. International Journal of Clinical Pharmacology and Therapeutics, 43 (7) pp. 339-349. Peer-reviewed.
 
Severe bruising as an adverse event: chocolate or fluvoxamine? Case report
Jaquenoud Sirot Eveline, Stephan P.L., Baumann Pierre, 2005. p. 55 dans , Pharmacopsychiatry. Peer-reviewed.
 
TDM and pharmacogenetic tests as tools in pharmacovigilance: case reports
Jaquenoud Sirot Eveline, Stephan P., Knezevic B., Eap Chin-Bin, Baumann Pierre, 2005. p. 54 dans , Pharmacopsychiatry. Peer-reviewed.
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants
Baumann Pierre, Ulrich Sven, Eckermann Gabriel, Gerlach Manfred, Kuss Hans-Joachim, Laux Gerd, Müller-Oerlinghausen Bruno, Rao Marie Luise, Riederer Peter, Zernig Gerald et al., 2005. Dialogues in Clinical Neuroscience, 7 (3) pp. 231-247. Peer-reviewed.
 
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry
Gaertner I., Baumann Pierre, Hiemke Christoph, Ulrich Sven, Eckermann Gabriel, Gerlach Manfred, Kuss Hans-Joachim, Laux Gerd, Müller-Oerlinghausen Bruno, Rao Marie Luise et al., 2005. p. 50 dans , Pharmacopsychiatry. Peer-reviewed.
 
Therapeutisches Drug-Monitoring (TDM) - Pharmakogenetick - Pharmakovigilanz
Baumann Pierre, Hiemke Christoph, 2005. Psychopharmakotherapie, 12 (4) pp. 111-112. Peer-reviewed.
 
Therapeutisches Drug-Monitoring in der Psychiatrie: Konsensus-Leitlinie der AGNP
Hiemke Christoph, Baumann Pierre, Laux Gerd, Kuss Hans-Joachim, 2005. Psychopharmakotherapie, 12 (5) pp. 166-182. Peer-reviewed.
 
Treatment of suicide attempters prior to hospital admission
Orha Florin A., Zullino Daniele Fabio, Baumann Pierre, 2005. Progress in Neuro-psychopharmacology & Biological Psychiatry, 29 (5) pp. 694-701. Peer-reviewed.
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
Fellay J., Marzolini C., Decosterd L., Golay K.P., Baumann P., Buclin T., Telenti A., Eap C.B., 2005. European journal of clinical pharmacology, 60 (12) pp. 865-73. Peer-reviewed.
 
Will genotyping and phenotyping methods replace TDM in the future?
Eap Chin-Bin, Baumann Pierre, 2005. p. 48 dans , Pharmacopsychiatry. Peer-reviewed.
 
Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS.
Paus E., Jonzier-Perey M., Cochard N., Eap C.B., Baumann P., 2004. Therapeutic drug monitoring, 26 (4) pp. 366-74. Peer-reviewed.
 
Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
Ciusani E., Zullino D.F., Eap C.B., Brawand-Amey M., Brocard M., Baumann P., 2004. Journal of Psychopharmacology, 18 (4) pp. 559-566. Peer-reviewed.
 
CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene.
Eap C.B., Fellay J., Buclin T., Bleiber G., Golay K.P., Brocard M., Baumann P., Telenti A., 2004. Pharmacogenetics, 14 (4) pp. 255-260. Peer-reviewed.
 
Death following acute poisoning by moclobemide
Giroud C., Horisberger B., Eap C., Augsburger M., Ménétrey A., Baumann P., Mangin P., 2004. Forensic science international, 140 (1) pp. 101-107. Peer-reviewed.
 
Determination of human plasma levels of levo-alpha-acetylmethadol and its metabolites by gas chromatography-mass spectrometry.
Eap C.B., Bouchoux G., Scherbaum N., Gastpar M., Powell Golay K., Baumann P., 2004. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 805 (1) pp. 141-6. Peer-reviewed.
 
Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry.
Eap C.B., Bouchoux G., Powell Golay K., Baumann P., 2004. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 802 (2) pp. 339-45. Peer-reviewed.
 
Die Bedeutung der Pharmakogenetik für die Psychopharmakotherapie
Baumann Pierre, Eap Chin-Bin, Jaquenoud Sirot Eveline, 2004. p. 322 dans , Der Nervenarzt. Peer-reviewed.
 
Die Bedeutung der Pharmakogenetik für die Psychopharmakotherapie
Baumann Pierre, Eap Chin-Bin, Jaquenoud Sirot Eveline, 2004. p. 322 dans , Der Nervenarzt. Peer-reviewed.
 
Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone
Benmebarek M., Devaud C., Gex-Fabry M., Powell Golay K., Brogli C., Baumann P., Gravier B., Eap C.B., 2004. Clinical pharmacology and therapeutics, 76 (1) pp. 55-63. Peer-reviewed.
 
Follow-up study using TDM and pharmacogenetic testing as tools in pharmacovigilance
Jaquenoud Sirot Eveline, Eap Chin-Bin, Baumann Pierre, 2004. pp. 937-937 dans , Drug Safety. Peer-reviewed.
 
From serotonin to clinical psychopharmacology and pharmacogenetics
Baumann Pierre, 2004. dans Reflections on twentieth-century psycho-pharmacology / ed. by Thomas A. Ban, David Healy, Edward Shorter. - Budapest : Animula, 2004. - P. 475-479. - (The history of psychopharmacology and the CINP, as told in atutobiography ; vol. 4). - ISBN 9639410497.
 
High dose of depot risperidone in a nonresponder schizophrenic patient.
Albrecht A., Morena P.G., Baumann P., Eap C.B., 2004. Journal of clinical psychopharmacology, 24 (6) pp. 673-4. Peer-reviewed.
 
High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency
Haller-Gloor Friedrich, Eap Chin-Bin, Turgeon Jacques, Baumann Pierre, 2004. International Journal of Psychiatry in Clinical Practice, 8 (3) pp. 191-195. Peer-reviewed.
 
Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.
Eap C.B., Bender S., Jaquenoud Sirot E., Cucchia G., Jonzier-Perey M., Baumann P., Allorge D., Broly F., 2004. Journal of clinical psychopharmacology, 24 (2) pp. 214-9. Peer-reviewed.
Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.
Eap C.B., Buclin T., Cucchia G., Zullino D., Hustert E., Bleiber G., Golay K.P., Aubert A.C., Baumann P., Telenti A. et al., 2004. European journal of clinical pharmacology, 60 (4) pp. 237-46. Peer-reviewed.
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects
Eap C.B., Buclin T., Hustert E., Bleiber G., Golay K.P., Aubert A.C., Baumann P., Telenti A., Kerb R., 2004. European journal of clinical pharmacology, 60 (4) pp. 231-236. Peer-reviewed.
 
Pharmacovigilance study in psychiatry involving TDM and pharmacogenetics
Jaquenoud Sirot Eveline, Eap Chin-Bin, Baumann Pierre, 2004. pp. I/22 dans , European Archives of Psychiatry and Clinical Neuroscience. Peer-reviewed.
 
Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response.
Nikisch G., Mathé A.A., Czernik A., Eap C.B., Jiménez-Vasquez P., Brawand-Amey M., Baumann P., 2004. Journal of clinical psychopharmacology, 24 (3) pp. 283-90. Peer-reviewed.
 
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., Kuss H.J., Laux G., Müller-Oerlinghausen B., Rao M.L. et al., 2004. Pharmacopsychiatry, 37 (6) pp. 243-265. Peer-reviewed.
 
The role of pharmacogenetics in the pharmacological treatment of psychiatric disorders
Eap Chin-Bin, Baumann Pierre, 2004. pp. I/13 dans , European Archives of Psychiatry and Clinical Neuroscience. Peer-reviewed.
 
Therapeutic drug monitoring and pharmacogenetics of psychotropic drugs
Baumann Pierre, Jaquenoud Sirot Eveline, Eap Chin-Bin, 2004. p. 116 dans , Clinical Chemistry and Laboratory Medicine. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University